Claudia Hochberg, MD
Interventional Cardiology · Boston, MANPI 1164402616
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,439 of the $62,642 with a category attached, or 93.3%. Shockwave Medical, Inc accounts for 93.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $58,250, more than ten times the $1,479 reported in 2019.
Across 30 payments — averaging $2088.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$58K
- Abiomed$3K
- Edwards Lifesciences$1K
- Abbott$189
Across 367 payments — averaging $598.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$183K
- Shockwave Medical, Inc$36K
- Neovasc Medical Inc$1K
What the payments were for
- Consulting fees$58,43993%
- Speaking & faculty fees$2,7504%
- Travel & lodging$1,0992%
- Food & beverage$3541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 7 | $58,250 |
| Abiomed | 3 | $2,763 |
| Edwards Lifesciences | 17 | $1,440 |
| Abbott | 3 | $189 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,750
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,005
- ABSORB$100
How this compares
$62,642 in reported general payments places this provider in the 80th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 70 | $64,874 |
| EntrestoSacubitril/Valsartan | 50 | $48,907 |
| Repatha SureclickEvolocumab | 49 | $28,416 |
| JardianceEmpagliflozin | 20 | $17,353 |
| FarxigaDapagliflozin Propanediol | 20 | $11,520 |
| Praluent PenAlirocumab | 12 | $5,903 |
| Metoprolol Succinate | 190 | $3,777 |
| Atorvastatin Calcium | 163 | $2,075 |
| Torsemide | 52 | $1,680 |
| Ezetimibe | 53 | $1,204 |
| Rosuvastatin Calcium | 55 | $1,134 |
| Losartan Potassium | 83 | $806 |
| Furosemide | 73 | $670 |
| Carvedilol | 36 | $645 |
| Lisinopril | 66 | $545 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.